A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck
This study has been withdrawn prior to enrollment.
( After loss of orphan drug status in Korea, study was withdrawn due to Regulatory Authority request. Patients will be enrolled into NCT01075828 instead. )
Study NCT01075841
Information provided by Merck KGaA
First Received on February 24, 2010.
Last Updated on December 7, 2010
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
